BRISTOL MYERS SQUIBB CO
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2seventy bio | 2seventy bio, Inc. | Merck | Merck & Co., Inc., Rahway, NJ, USA |
|---|---|---|---|
| ANDA | Abbreviated New Drug Application | MF | myelofibrosis |
| AOCL | Accumulated other comprehensive loss | Mirati | Mirati Therapeutics, Inc. |
| AstraZeneca | AstraZeneca PLC | MM | multiple myeloma |
| AVD | doxorubicin, vinblastine and dacarbazine | MZL | marginal zone lymphoma |
| BioArctic | BioArctic AB | NDA | New Drug Application |
| BioNTech | BioNTech SE | NSCLC | non-small cell lung cancer |
| Celgene | Celgene Corporation | NYHA | New York Heart Association |
| CELMoD | cereblon E3 ligase modulator | oHCM | Obstructive Hypertrophic Cardiomyopathy |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | Ono | Ono Pharmaceutical Co., Ltd |
| cHL | classical Hodgkins Lymphoma | PD-1 | programmed cell death protein 1 |
| CRC | colorectal cancer | PD-L1 | programmed death-ligand 1 |
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act |
| Dr. Reddy's Laboratories | Dr. Reddy's Laboratories, Limited and Dr. Reddy's Laboratories, Inc. | Philochem | Philochem AG |
| DVd | daratumumab, bortezomib and dexamethasone | Pfizer | Pfizer, Inc. |
| EC | European Commission | PFS | progression-free survival |
| EPS | earnings per share | PsA | psoriatic arthritis |
| ESCC | esophageal squamous cell carcinoma | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 |
| ES-SCLC | extensive stage small cell lung cancer | R&D | research and development |
| EU | European Union | RDFV | readily determinable fair values |
| Evotec | Evotec SE | REMS | risk evaluation and mitigation strategy |
| Exchange Act | the Securities Exchange Act of 1934 | Roche | F. Hoffman-La Roche & Co. |
| FASB | Financial Accounting Standards Board | RRMM | relapsed or refractory multiple myeloma |
| FDA | U.S. Food and Drug Administration | Sanofi | Sanofi S.A. |
| GAAP | generally accepted accounting principles | SAR | Special Administrative Region |
| GEP-NETs | gastroenteropancreatic neuroendocrine tumors | SEC | U.S. Securities and Exchange Commission |
| GTN | gross-to-net | SPC | Supplementary Protection Certificate |
| HCM | hypertrophic cardiomyopathy | SSTR+ | somatostatin receptor-positive |
| Hengrui | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | SystImmune | SystImmune, Inc. |
| HHS | Health and Human Services | TNBC | triple negative breast cancer |
| IPF | idiopathic pulmonary fibrosis | UK | United Kingdom |
| IPRD | in-process research and development | U.S. | United States |
| IRA | Inflation Reduction Act of 2022 | VAT | value added tax |
| IRS | Internal Revenue Service | VEGF-A | Vascular endothelial growth factor A |
| IT | Information Technology | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.